Wei Lin 4
4 · Revolution Medicines, Inc. · Filed Jun 18, 2025
Insider Transaction Report
Form 4
Wei Lin
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-06-16$39.83/sh−2,173$86,551→ 90,499 total
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
- [F2]This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
- [F4]Includes 64,800 RSUs.